These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1215 related articles for article (PubMed ID: 15751763)

  • 21. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
    Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M
    HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
    Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
    Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
    Dragsted UB; Mocroft A; Vella S; Viard JP; Hansen AB; Panos G; Mercey D; Machala L; Horban A; Lundgren JD;
    J Infect Dis; 2004 Jul; 190(1):148-55. PubMed ID: 15195254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
    Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
    J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    Antivir Ther; 2004 Apr; 9(2):229-35. PubMed ID: 15134185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
    AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
    Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
    AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
    Moore DM; Hogg RS; Chan K; Tyndall M; Yip B; Montaner JS
    AIDS; 2006 Feb; 20(3):371-7. PubMed ID: 16439870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
    Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
    Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    Roca B; Gómez CJ; Arnedo A
    J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.